Lonsurf 15 mg/6.14 mg film-coated tablets, IRINOTECAN, Bemarituzumab, PACLITAXEL, RAMUCIRUMAB
Phase 2 small_molecule active
Quick answer
Lonsurf 15 mg/6.14 mg film-coated tablets, IRINOTECAN, Bemarituzumab, PACLITAXEL, RAMUCIRUMAB for FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active